Subsequent experiments on endometrial cancer cell lines (HEC-1-A and Ishikawa) produced contradictory results: silencing SESN2 in these cell lines enhanced mTORC1 activity, increased proliferation, and raised intracellular ROS levels. Here, SESN2 is linked to endometrial cancer.